These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33208690)

  • 1. A Comprehensive Overview of the Clinical Relevance and Treatment Options for Antibody-mediated Rejection Associated With Non-HLA Antibodies.
    Kardol-Hoefnagel T; Otten HG
    Transplantation; 2021 Jul; 105(7):1459-1470. PubMed ID: 33208690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients.
    Everly MJ
    Clin Transpl; 2011; ():319-25. PubMed ID: 22755425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization.
    Choi AY; Manook M; Olaso D; Ezekian B; Park J; Freischlag K; Jackson A; Knechtle S; Kwun J
    Front Immunol; 2021; 12():694763. PubMed ID: 34177960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers.
    Joher N; Matignon M; Grimbert P
    Front Immunol; 2021; 12():688301. PubMed ID: 34093594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annual literature review of donor-specific HLA antibodies after organ transplantation.
    Kaneku H
    Clin Transpl; 2011; ():311-8. PubMed ID: 22755424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desensitization for solid organ and hematopoietic stem cell transplantation.
    Zachary AA; Leffell MS
    Immunol Rev; 2014 Mar; 258(1):183-207. PubMed ID: 24517434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients.
    OʼLeary JG; Samaniego M; Barrio MC; Potena L; Zeevi A; Djamali A; Cozzi E
    Transplantation; 2016 Jan; 100(1):39-53. PubMed ID: 26680372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying HLA-specific antibodies in patients undergoing desensitization.
    Zachary A; Reinsmoen NL
    Curr Opin Organ Transplant; 2011 Aug; 16(4):410-5. PubMed ID: 21666475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desensitization in the Setting of HLA-Incompatible Kidney Transplant.
    Malvezzi P; Jouve T; Noble J; Rostaing L
    Exp Clin Transplant; 2018 Aug; 16(4):367-375. PubMed ID: 29863455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the histocompatibility laboratory in desensitization for transplantation.
    Leffell MS; Zachary AA
    Curr Opin Organ Transplant; 2009 Aug; 14(4):398-402. PubMed ID: 19417655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence of donor-specific antibodies in renal transplantation.
    Tozkir H; Sağiroğlu T; Kiliçarslan-Ayna T; Tan S; Çopuroğlu E; Sağiroğlu G; Sari G; Gürkan H; Sezer A
    Transplant Proc; 2012; 44(6):1667-9. PubMed ID: 22841240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of antibodies in kidney transplant].
    Ruffoni E; Seveso M; Marson P; Tison T; Cozzi E
    G Ital Nefrol; 2012; 29 Suppl 54():S54-60. PubMed ID: 22388831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summarizing the use of donor specific anti-HLA antibody monitoring in transplant patients.
    Everly MJ
    Clin Transpl; 2011; ():333-6. PubMed ID: 22755427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
    Vo AA; Zeevi A; Choi J; Cisneros K; Toyoda M; Kahwaji J; Peng A; Villicana R; Puliyanda D; Reinsmoen N; Haas M; Jordan SC
    Transplantation; 2015 Feb; 99(2):299-308. PubMed ID: 25606785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modifiers of complement activation for prevention of antibody-mediated injury to allografts.
    Hughes PD; Cohney SJ
    Curr Opin Organ Transplant; 2011 Aug; 16(4):425-33. PubMed ID: 21681097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
    Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-Specific Antibodies in Kidney Transplant Recipients.
    Zhang R
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):182-192. PubMed ID: 28446536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.